Velcade Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma
CONCLUSION: A systematic analysis of NRGs can help identify potential necroptosis-related mechanisms and provide novel biomarkers for MM prognosis prediction, tumor microenvironment evaluation, and personalized treatment planning.PMID:38361483 | PMC:PMC10874153 | DOI:10.1177/15330338241232554 (Source: Technology in Cancer Research and Treatment)
Source: Technology in Cancer Research and Treatment - February 16, 2024 Category: Cancer & Oncology Authors: Jun-Yao Jiang Fang-Yi Yao Jing Liu Xin-Lu Wang Bo Huang Fang-Min Zhong Xiao-Zhong Wang Source Type: research

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284089. Online ahead of print.ABSTRACTThe treatment landscape for multiple myeloma has significantly evolved in the last decade. Notwithstanding, a large proportion of patients continue to relapse and novel combinations continue to be needed. In this phase 2 study, selinexor, a first-in-class inhibitor of exportin-1 was evaluated in combination with standard daratumumab-bortezomib-dexamethasone (DVd), for the treatment of relapsed and refractory multiple myeloma (RRMM). The aim of the trial was to assess the efficacy and safety of the combination of selinexor with DVd ...
Source: Haematologica - February 15, 2024 Category: Hematology Authors: Ver ónica González-Calle Paula Rodr íguez-Otero Anna Sureda Felipe De Arriba Marta Reinoso Paz Ribas Ana Pilar Gonz ález-Rodríguez Yolanda Gonz ález Albert Oriol Joaqu ín Martínez-López Marta Sonia Gonz ález Miguel T Hern ández Maialen Sirvent Source Type: research

Potential mechanisms and drug prediction of Rheumatoid Arthritis and primary Sj ögren’s Syndrome: A public databases-based study
In conclusion, we identified commom targets as potential biomarkers in RA and pSS from publicly available databases and predicted potential drugs based on the targets. A new understanding of the molecular mechanisms associated with RA and pSS is provided according to the miRNA–gene network. (Source: PLoS One)
Source: PLoS One - February 15, 2024 Category: Biomedical Science Authors: Li Wu Source Type: research

The cost of multiple myeloma and its complications: a single-center study from Oran, Algeria
CONCLUSION: A number of adjustments have been implemented to the management of MM over time to improve clinical efficacy and reduce costs in Algeria. However, this may have come with a startlingly high cost of complications.PMID:38340806 | DOI:10.1016/j.pharma.2024.02.001 (Source: Annales Pharmaceutiques Francaises)
Source: Annales Pharmaceutiques Francaises - February 10, 2024 Category: Drugs & Pharmacology Authors: Fairouz Haouatti Ikram K Belhadj Ahlem Goumidi Nabil Yafour Toumi Houari Source Type: research

Improved Outcome of Primary Plasma Cell Leukemia in the Current Era with the Use of Novel Agents and Autologous Bone Marrow Transplants —A Single Centre Experience
AbstractPrimary Plasma cell leukemia (pPCL) is an aggressive variant of plasma cell dyscrasias. Diagnostic criteria of plasma cell leukemia were recently updated by international myeloma working group to with more than 5% circulating plasma cells or absolute plasma cell count of more than 500/ µL.We performed a retrospective analysis of patients diagnosed with pPCL in our department from 2017 to 2022. Clinical characteristics including the symptoms at presentation, organomegaly, bony involvement and extramedullary involvement were collected. Laboratory parameters including the biochemistry serum protein electrophoresis, s...
Source: Indian Journal of Hematology and Blood Transfusion - February 5, 2024 Category: Hematology Source Type: research

Cancers, Vol. 16, Pages 670: Bortezomib in Combination with Physachenolide C Reduces the Tumorigenic Properties of KRASmut/P53mut Lung Cancer Cells by Inhibiting c-FLIP
Conclusion: These findings demonstrate that PCC sensitizes cancer cells to bortezomib, potentially improving the antitumor effects against KRASmut/P53mut lung cancer cells, with an enhanced efficacy of combination treatments without causing significant side effects. (Source: Cancers)
Source: Cancers - February 4, 2024 Category: Cancer & Oncology Authors: Thanigaivelan Kanagasabai Zerick Dunbar Salvador Gonz ález Ochoa Tonie Farris Sivanesan Dhandayuthapani E. M. Kithsiri Wijeratne A. A. Leslie Gunatilaka Anil Shanker Tags: Article Source Type: research

Acquired von Willebrand syndrome in a patient with monoclonal gammopathy of unknown significance: A case report
We present a patient who achieved durable remission through eradication of the monoclonal paraprotein with clonal directed therapy with bortezomib. (Source: Clinical Case Reports)
Source: Clinical Case Reports - February 3, 2024 Category: General Medicine Authors: Garima Gupta, Janeesh Sekkath Veedu, Zena Chahine, Chaitanya Iragavarapu Tags: CASE REPORT Source Type: research

VD-PACE As Salvage and Bridging Therapy to Transplant and Cellular Therapy in Triple Class Relapsed/Refractory Multiple Myeloma
Patients that have triple-class relapsed/refractory multiple myeloma (RRMM) have relapsed on each of the following classes: immunomodulatory drugs, proteasome inhibitors, and an anti-CD38 monoclonal antibody. RRMM poses a significant challenge with poor prognosis due to limited options. We evaluated VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) for efficacy and safety as salvage therapy in heavily pretreated RRMM. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Priyanka Venkatesh, Polina Bellman, Sara Shatnawi, Yara Shatnawi, Hira Shaikh, Christopher Sun Strouse, Shebli Atrash, Hamza Hashmi, Muhammad Umair Mushtaq, Nausheen Ahmed, Zahra Mahmoudjafari, Al-Ola Abdallah, Leyla Shune Tags: 534 Source Type: research

Favourable Outcomes for Carfilzomib-Melphalan and Bortezomib-Melphalan Conditioned Autologous Hematopoietic Stem Cell (AHCT) Transplants in Relapsed/Primary Refractory Myeloma: An Australian Single Centre Real-World Experience
Despite improvements in the treatment options for myeloma, transplant eligible patients with primary refractory or relapsed disease have inferior outcomes. As there is evidence for synergy and safety for the combination of proteasome inhibitors and melphalan, bortezomib or carfilzomib is added to melphalan conditioning for these high-risk patients prior to AHCT in our institution. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Brydon Panozzo, Jeremy Er, David Routledge, Trish Joyce, Simon J Harrison, Amit Khot Tags: 529 Source Type: research

Cost per Responder Analysis of Patients with Lenalidomide-Refractory Multiple Myeloma Who Received Cilta-Cel from the Cartitude-4 Trial
Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor-T cell (CAR-T) immunotherapy approved for patients (pts) with relapsed/refractory multiple myeloma (RRMM). In the phase 3 trial CARTITUDE-4 (NCT04181827), cilta-cel demonstrated improved efficacy vs standard of care (SOC; daratumumab plus pomalidomide and dexamethasone [DPd] or pomalidomide plus bortezomib and dexamethasone [PVd]) with an overall response rate (ORR) of 84.6% vs 67.3% and ≥complete response (CR) of 73.1% vs 21.8%. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Doris K Hansen, Xiaoxiao Lu, Omar Castaneda, Sonja Sorensen, Saad Z. Usmani, Eileen Zhang, Stephen Huo, Sundar Jagannath Tags: 519 Source Type: research